Acceder

Bibliografías temáticas / Metformin Gastrointestinal Intolerability Adherence

Índice

Artículos de revistas

Literatura académica sobre el tema "Metformin Gastrointestinal Intolerability Adherence"

Autor: Grafiati

Publicado: 7 de junio de 2025

Última modificación: 2 de agosto de 2025

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Metformin Gastrointestinal Intolerability Adherence".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Metformin Gastrointestinal Intolerability Adherence"

1

Tapas, Kumar Mohapatra* Akankshya Raul Soumyashree Dehury Rajesh Kumar Pothal. "Advancements in Osmotic Controlled Drug Delivery Systems and Their Role in Diabetes Management." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 1410–22. https://doi.org/10.5281/zenodo.15379161.

Texto completo

Resumen

A new and very successful method for improving the therapeutic results of oral drugs is Osmotic Controlled Drug Delivery Systems (OSMO) technology. This is especially true when it comes to the treatment of chronic conditions like Type 2 Diabetes Mellitus (T2DM). Regardless of the pH or motility of the gastrointestinal tract, these systems use osmotic pressure to distribute medications in a regulated and prolonged way. The fundamental benefit of OSMO technology is its capacity to keep plasma drug concentrations constant, reducing variations that may result in adverse effects or diminished effec

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Cheah, Zhen Fung, and Yueh Chien Kuan. "LBODP033 The Compliant Patient - When Adherence Hurts." Journal of the Endocrine Society 6, Supplement_1 (2022): A264—A265. http://dx.doi.org/10.1210/jendso/bvac150.543.

Texto completo

Resumen

Abstract Metformin is a biguanide oral antidiabetic agent which lowers blood glucose by decreasing hepatic gluconeogenesis. In the absence of contraindications, it is the initial treatment in most patients with type 2 diabetes along with lifestyle modifications. This drug however is commonly associated with gastrointestinal side effects especially diarrhoea which could be potentially life-threatening if prolonged. We report a case of chronic severe painless diarrhoea with weight loss over 8 months in a 40-year-old man after starting metformin for his newly diagnosed type 2 diabetes. Although t

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Mounazza Rehman, Qudsia Nawaz, Siddiqa Batool, Faiza Khanum, Sehrish Raja, and Munnaza Andleeb. "Efficacy of Metformin and Combination of Metformin and Myo-Inositol on Clinical and Hormonal Profile of Polycystic Ovarian Disease Patient." Indus Journal of Bioscience Research 3, no. 3 (2024): 713–17. https://doi.org/10.70749/ijbr.v3i3.933.

Texto completo

Resumen

Background: The widespread endocrine condition known as polycystic ovarian syndrome (PCOS) is typified by hyperandrogenism, insulin resistance, and reproductive failure. Metformin, a commonly used insulin sensitizer, has showed benefits in controlling PCOS but is often linked with gastrointestinal adverse effects. Another insulin-sensitizing drug that has drawn interest is myo-inositol because of its superior tolerability and comparable effectiveness. The purpose of this study is to compare the clinical and hormonal effects of metformin monotherapy against myo-inositol combination treatment in

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Ainan Arshad, Kashif Khan, and Muhammad Shoaib. "The synergy of linagliptin and empagliflozin in catering to diabetes mellitus in Pakistan." Journal of the Pakistan Medical Association 75, no. 02 (2025): 284–86. https://doi.org/10.47391/jpma.11145.

Texto completo

Resumen

Diabetes is rapidly increasing globally, especially in low- and middle-income countries, with Pakistan ranking third in prevalence, having 33 million people. The lack of adherence to the first-line treatment, metformin, mainly due to gastrointestinal side effects, is a significant concern. A novel approach for managing type 2 diabetes in Pakistan is to combine linagliptin and empagliflozin. Linagliptin is well-tolerated and suitable for those who cannot tolerate metformin, while empagliflozin reduces cardiovascular risks and nephropathy, showing promising results in controlling diabetes with m

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Chawla, Manoj, Purvi Chawla, Pratap Jethwani, Kiran Shah, and Sanjay Reddy. "Metformin Sustained-Release and Vildagliptin Fixed-Dose Combination for Optimizing Glycemic Control: A Review with Real-World Case Reports." Clinics and Practice 13, no. 2 (2023): 497–504. http://dx.doi.org/10.3390/clinpract13020045.

Texto completo

Resumen

(1) Background: There is a high burden of poor glycemic control in the Indian population with type 2 diabetes mellitus (T2DM). Currently, the use of metformin sustained-release (SR)–vildagliptin fixed-dose combination (FDC) is very low as compared to metformin immediate-release (IR)–vildagliptin FDC which is associated with higher adverse events (AEs). Here, we present real-world effectiveness of metformin SR–vildagliptin FDC treatment in patients with T2DM; (2) Methods: This retrospective analysis was carried out from the medical records of adult T2DM patients visiting a single study center i

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Shivaraj, Gurupadappa Sajjanshetty. "A Study on the Reduction of Type-2 Diabetes Incidence with Metformin and Lifestyle Modification." International Journal of Pharmaceutical and Clinical Research 15, no. 10 (2023): 1358–66. https://doi.org/10.5281/zenodo.11295886.

Texto completo

Resumen

<strong>Introduction: </strong>This study discusses how DM causes persistent hyperglycemia due to insulin resistance or decreased production. In 2015, there were 415 million cases of DM while by 2040, morethan   200 millions of DM patients will be added. Diabetes and hyperglycemia damage organs, raising coronary disease risk. The three primary kinds of DM are T1DM (autoimmune-driven insulin loss), T2DM (insulin resistance), and gestational DM. The main T2DM treatment is metformin. <strong>Aim and Objectives:</strong> This study aims to assess the effectiveness of metfo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Eskin, Fatih, and Duygu Tutan. "Is there a relationship between metformin-related gastrointestinal symptoms and vitamin B12 deficiency in patients with type 2 diabetes mellitus?" Medicine Science | International Medical Journal 12, no. 1 (2023): 324. http://dx.doi.org/10.5455/medscience.2023.02.025.

Texto completo

Resumen

Metformin (MTF) associated gastrointestinal symptoms are fairly common side effects that adversely affect patients' treatment adherence. However, the variability of gastrointestinal symptoms in MTF-using patients has not been fully explained. In our study, we aimed to investigate the relationship between vitamin B12 deficiency with MTF-related gastrointestinal symptoms. Patients with type 2 diabetes mellitus (T2DM) using MTF were included in the study sequentially. Demographic characteristics of the patients, duration of diabetes, MTF dose and duration used, and gastrointestinal symptoms were

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Anderson, Jemma J. A., Jennifer J. Couper, Lynne C. Giles, et al. "Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial." Journal of Clinical Endocrinology & Metabolism 102, no. 12 (2017): 4448–56. http://dx.doi.org/10.1210/jc.2017-00781.

Texto completo

Resumen

Abstract Context Children with type 1 diabetes have vascular dysfunction preceding atherosclerosis. Early interventions are needed to reduce cardiovascular disease. Objective To evaluate the effect of metformin on vascular function in children with type 1 diabetes. Design Twelve-month double-blind, randomized, placebo-controlled trial. Setting Tertiary pediatric diabetes clinic. Participants Ninety children (8 to 18 years of age), &gt;50th percentile body mass index (BMI), with type 1 diabetes. Intervention Metformin (up to 1 g twice a day) or placebo. Main Outcome Measure Vascular functio

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Florez, Hermes, Jiacong Luo, Sumaya Castillo-Florez, et al. "Impact of Metformin-Induced Gastrointestinal Symptoms on Quality of Life and Adherence in Patients with Type 2 Diabetes." Postgraduate Medicine 122, no. 2 (2010): 112–20. http://dx.doi.org/10.3810/pgm.2010.03.2128.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Mario Alberto Ramírez-Camacho, Luis Alberto Soberanis-Monsreal, Abraham Arcos-Díaz, et al. "Adverse drug reactions and medication adherence to oral antidiabetic drugs in patients: A longitudinal study." International Journal of Biological and Pharmaceutical Sciences Archive 9, no. 1 (2025): 077–84. https://doi.org/10.53771/ijbpsa.2025.9.1.0033.

Texto completo

Resumen

The World Health Organization (WHO) has indicated that treatment adherence in most patients with type 2 diabetes (T2D) is low and may be affected by the presence of adverse drug reactions (ADRs) associated with hypoglycemic pharmacotherapy The aim of this study was to analyze the relationship between the degree of pharmacotherapeutic adherence and the appearance of ADRs in people with T2D. A three-month prospective study was conducted, in which pharmacotherapeutic adherence was assessed using an indirect method, while ADRs were identified and characterized through active pharmacovigilance in o

Los estilos APA, Harvard, Vancouver, ISO, etc.

Más fuentes

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!